Skip to main content
108 results:
71. SphingoTec Issues Convertible Note Facility  
Diagnostic company SphingoTec GmbH (SphingoTec) today announced that the Company has issued a non-brokered, unsecured convertible note facility amounting to EUR 5 million that was fully subscribed by…  
72. SphingoTec to present at Solebury Trout's Summer Private Company Showcase  
Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced that Dr Andreas Bergman, CEO, and Ferdinand Von Humboldt, CFO, will be  presenting a corporate overview at the Summer Private…  
73. SphingoTec to present at LifeSci Partners' Summer Symposium  
Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced that Dr Andreas Bergman, CEO, and Ferdinand von Humboldt, CFO, will be presenting a corporate overview at the Private Healthcare…  
74. SphingoTec launches point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction  
Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced the launch of its IB10 sphingotest® bio-ADM®, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of…  
75. Sphingotec’s critical care biomarkers early diagnose risk of loss of endothelial, kidney and heart function in severely ill COVID-19 patients  
Diagnostics company SphingoTec GmbH (“sphingotec”) announced today the results of a working group meeting of clinical experts that discussed the utility of sphingotec’s diagnostic solutions for acute…  
76. The cardiac depressant factor DPP3 is predicting organ failure in burn patients  
Diagnostics company SphingoTec GmbH (“sphingotec”) and 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3…  
77. sphingotec expands leadership team and appoints Achim Plum as Managing Director and Chief Commercial Officer  
Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf, Germany) today announced that it has appointed Dr. Achim Plum as Managing Director and Chief Commercial Officer (CCO) of the company.  
78. SphingoTec's endothelial function biomarker bio-ADM® improves risk stratification of sepsis patients at ICUs  
Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf Germany) today reported on new data on the utility of endothelial function biomarker bioactive Adrenomedullin (bio-ADM®).   
79. Bioactive Adrenomedullin, measured with sphingotec’s bio-ADM® assay plays a key role in septic shock patients as top-line results of AdrenOSS-2 Phase II Study indicate  
Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf, Germany) today announced that data from the AdrenOSS-2 study indicate a modulating role of bioactive Adrenomedullin in septic…  
80. Novel Data on SphingoTec's Biomarkers for acute and critical care setting to be presented at AKI & CRRT 2020  
SphingoTec GmbH (“sphingotec”) today announced that novel data on its acute care biomarkers Proenkephalin (penKid®) and Dipeptidyl Peptidase 3 (DPP3) will be presented at the 25th International…  
Search results 71 until 80 of 108